Dopamine D2 receptor agonists abrogate neuroendocrine tumour angiogenesis to inhibit chemotherapy-refractory small cell lung cancer progression
Sk. Kayum Alam, Anuradha Pandit, Li Wang, Seyedeh Sahar Mortazavi Farsani, Brittney Thiele, Parvathy Manoj, Marie Christine Aubry, Vivek Verma, Charles M. Rudin, Ying‐Chun Lo, Luke H. Hoeppner
This study shows that dopamine D2 receptor agonists reduce angiogenesis and inhibit chemotherapy-refractory small cell lung cancer progression by targeting tumour-associated endothelial cells.
Cell Death and Disease · May 9, 2025Peer-reviewedCancer Biology